Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD, USA
Список исп. литературыСкрыть список 1. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937;94: 577-85. 2. Griffiths AO. Enuresis and tricyclic antidepressants. Br Med J 1979;1:1213. 3. Rapoport JL, Buchsbaum MS, Zahn TP et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978;199:560-3. 4. Rapoport JL, Buchsbaum MS, Weingartner H et al. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980;37:933-43. 5. Porrino LJ, Rapoport JL, Behar D et al. A naturalistic assessment of the motor activity of hyperactive boys. II. Stimulant drug effects. Arch Gen Psychiatry 1983; 40:688-93. 6. Barkley RA. Hyperactive girls and boys: stimulant drug effects on mother-child interactions. J Child Psychol Psychiatry 1989;30:379-90. 7. Wells KC, Chi TC, Hinshaw SP et al. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol 2006;74:649-57. 8. Johnston C, Pelham WE Jr. Maternal characteristics, ratings of child behavior, and mother-child interactions in families of children with externalizing disorders. J Abnorm Child Psychol 1990;18:407-17. 9. Flynn N, Rapoport J. Hyperactivity in open and traditional classroom environments. J Spec Ed 1976;10:286-90. 10. Hechtman L, Weiss G, Finklestein J et al. Hyperactives as young adults: preliminary report. Can Med Assoc J 1976;115: 625-30. 11. Mannuzza S, Klein RG, Bonagura N et al. Hyperactive boys almost grown up. II. Status of subjects without a mental disorder. Arch Gen Psychiatry 1988;45: 13-8. 12. Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994; 151:633-8. 13. Mikkelsen EJ, Rapoport JL. Enuresis: psychopathology, sleep stage, and drug response. Urol Clin North Am 1980;7: 361-77. 14. Puig-Antich JP, Perel JM, Chambers WJ. Imipramine treatment of prepubertal major depressive disorders: plasma levels and clinical response – preliminary report. Psychopharmacol Bull 1980;16: 25-7. 15. Kashani JH, Husain A, Shekim WO et al. Current perspectives on childhood depression: an overview. Am J Psychiatry 1981; 138:143-53. 16. Cytryn L, McKnew DH. Treatment issues in childhood depression. Pediatr Ann 1986; 15:856-8. 17. Copeland WE, Shanahan L, Costello EJ et al. Childhood and adolescent psychiatric disorders as predictors of young adult disorders. Arch Gen Psychiatry 2009;66: 764-72. 18. Stringaris A, Cohen P, Pine DS et al. Adult outcomes of youth irritability: a 20-year prospective community-based study. Am J Psychiatry 2009;166:1048-54. 19. Kovacs M, Feinberg TL, Crouse-Novak MA et al. Depressive disorders in childhood. I. A longitudinal prospective study of characteristics and recovery. Arch Gen Psychiatry 1984;41:229-37. 20. Rush AJ, Kovacs M, Beck AT et al. Differ- ential effects of cognitive therapy and pharmacotherapy on depressive symptoms. J Affect Disord 1981;3:221-9. 21. Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992;31:21-8. 22. Pine DS, Helfinstein SM, Bar-Haim Y et al. Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety. Neuropsychopharmacology 2009;34:213-28. 23. de Beurs E, van Balkom AJ, Lange A et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-91. 24. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry 2004;65:1696-707. 25. Flament MF, Rapoport JL, Berg CJ et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 1985;42: 977-83. 26. Lenane MC, Swedo SE, Leonard H et al. Psychiatric disorders in first degree relatives of children and adolescents with obsessive compulsive disorder. J Am Acad Child Adolesc Psychiatry 1990;29: 407- 12. 27. Swedo SE, Leonard HL, Rapoport JL. Childhood-onset obsessive compulsive disorder. Psychiatr Clin North Am 1992;15: 767-75. 28. Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004;113:907-11. 29. Findling RL, Horwitz SM, Birmaher B et al. Clinical characteristics of children receiving antipsychotic medication. J Child Adolesc Psychopharmacol 2011; 21:311-9. 30. 30. Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000; 1:935-45. 31. McClellan J, Sikich L, Findling RL et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007;46:969-78. 32. Findling RL, Johnson JL, McClellan J et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010;49:583-94. 33. Domino ME, Burns BJ, Silva SG et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry 2008;165:588-96. 34. Zito JM, Safer DJ, de Jong-van den Berg LT et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26. 35. Zito JM, Safer DJ. Recent child pharmacoepidemiological findings. J Child Adolesc Psychopharmacol 2005;15:5-9. 36. Zito JM. Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology. J Clin Psy- chiatry 2007;68:966-7. 37. Zito JM, Safer DJ, dosReis S et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000;283: 1025-30. 38. Angold A, Erkanli A, Egger HL et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 2000;39:975-84. 39. Costello EJ, Mustillo S, Erkanli A et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 2003;60: 837- 44. 40. Mannuzza S, Klein RG, Truong NL et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165:604-9. 41. Swanson J, Greenhill L, Wigal T et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006;45:1304-13. 42. Frauger E, Pauly V, Natali F et al. Pat- terns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs 2011;25:415-24. 43. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008;10:111. 44. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:537-45. 45. Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. 46. Kumra S, Frazier JA, Jacobsen LK et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090- 7. 47. Shaw P, Sporn A, Gogtay N et al. Child- hood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine compar- ison. Arch Gen Psychiatry 2006; 63:721-30. 48. Sporn AL, Vermani A, Greenstein DK et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007;46:1349-56. 49. Thapar A, Collishaw S, Pine DS et al. Depression in adolescence. Lancet 2012; 379:1056-67. 50. Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40:762-72. 51. Pine DS. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 2002; 12:189-203. 52. Bridge JA, Iyengar S, Salary CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-96. 53. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9. 54. Vasa RA, Carlino AR, Pine DS. Pharmacotherapy of depressed children and adolescents: current issues and potential directions. Biol Psychiatry 2006;59:1021- 8. 55. Meyer RE, Salzman C, Youngstrom EA et al. Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010; 71:e1-21. 56. Sanacora G, Kendell SF, Levin Y et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61:822-5. 57. Festoff BW. Amyotrophic lateral sclerosis: current and future treatment strategies. Drugs 1996;51:28-44. 58. Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2010;20:309- 15. 59. Grant P, Lougee L, Hirschtritt M et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17:761-7. 60. Grant PL. Personal communication, July 2012. 61. Smalley S, Smith M, Tanguay P. Autism and psychiatric disorders in tuberous sclerosis. Ann N Y Acad Sci 1991; 615:382-3. 62. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011;480:63-8. 63. Ehninger D, Silva AJ. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med 2011;17:78-87. 64. Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 2005;4:393-8. 65. Doolen G, Carpenter RL, Ocain TD et al. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010;127:78- 93. 66. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol 2012;4(3). 67. Voineagu I, Wang X, Johnston P et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011;474:380-4. 68. Jaddoe VW, van Duijn CM, van der Heij- den AJ et al. The Generation R Study: design and cohort update 2010. Eur J Epidemiol 2010;25:823-41. 69. Center for Human Development, UC San Diego. Pediatric Longitudinal Imaging, Neurocognition, and Genetics (PLING). www.chd.ucsd.edu. 70. Gur RC, Richard J, Calkins ME et al. Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology 2012; 26:251-65. 71. Sanislow CA, Pine DS, Quinn KJ et al. Developing constructs for psychopathology research: Research Domain Criteria. J Abnorm Psychol 2010;119:631-9. 72. Regier DA, Narrow WE, Kuhl EA et al. The conceptual development of DSM-V. Am J Psychiatry 2009;166:645-50. 73. Insel T, Cuthbert B, Garvey M et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167: 748-51. 74. Craske MG. The R-DoC initiative: science and practice. Depress Anxiety 2012; 29:253-6. 75. Greenwood TA, Lazzeroni LC, Murray SS et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011; 168:930-46. 76. Marchetto MC, Winner B, Gage FH. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet 2010;19:R71-6. 77. Brennand KJ, Simone A, Tran N et al. Modeling psychiatric disorders at the cellular and network levels. Mol Psychiatry 2012;17:1239-53. 78. Eisenberg L. Past, present, and future of psychiatry: personal reflections. Can J Psychiatry 1997;42:705-13.